Analgesics in New Zealand

October 2023 | 25 pages | ID: A327AE5B821EN
Euromonitor International Ltd

Abstracts

Analgesics continued to see solid growth in current value terms in 2023, following the easing of most COVID-19-related restrictions in September 2022. With measures such as lockdowns, mandatory mask-wearing and social distancing no longer in place, the virus was able to spread quickly through the population. Moreover, with the symptoms being relatively mild in most cases, consumers turned to OTC analgesics for relief.

Euromonitor International's Analgesics in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. Forecasts to 2027 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Analgesics market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Analgesics in New Zealand
Euromonitor International
October 2023

LIST OF CONTENTS AND TABLES

ANALGESICS IN NEW ZEALAND
KEY DATA FINDINGS

2023 DEVELOPMENTS

Early start to the flu season results boosts demand for analgesics
Panadol and Nurofen remain the go-to choices for analgesics among New Zealanders
Supermarkets and pharmacies share sales of analgesics
PROSPECTS AND OPPORTUNITIES
Older demographic will be key element of growth for pain relieving medicines
GSK Consumer Healthcare trials natural, plant-based analgesic in keeping with consumer demand for more ‘natural’ products
Incumbent brands to strengthen their hold over the market
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2018-2023
Table 2 Sales of Analgesics by Category: % Value Growth 2018-2023
Table 3 NBO Company Shares of Analgesics: % Value 2019-2023
Table 4 LBN Brand Shares of Analgesics: % Value 2020-2023
Table 5 Forecast Sales of Analgesics by Category: Value 2023-2028
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2023-2028
CONSUMER HEALTH IN NEW ZEALAND
EXECUTIVE SUMMARY
Consumer health in 2023: The big picture

2023 KEY TRENDS

Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2018-2023
Table 8 Life Expectancy at Birth 2018-2023
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2018-2023
Table 10 Sales of Consumer Health by Category: % Value Growth 2018-2023
Table 11 NBO Company Shares of Consumer Health: % Value 2019-2023
Table 12 LBN Brand Shares of Consumer Health: % Value 2020-2023
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2018-2023
Table 14 Distribution of Consumer Health by Format: % Value 2018-2023
Table 15 Distribution of Consumer Health by Format and Category: % Value 2023
Table 16 Forecast Sales of Consumer Health by Category: Value 2023-2028
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2023-2028
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources